Miller Z - Search Results

1

Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.

Lee MJ, Bhattarai D, Jang H, Baek A, Yeo IJ, Lee S, Miller Z, Lee S, Hong JT, Kim DE, Lee W, Kim KB. Lee MJ, et al. Among authors: miller z. J Med Chem. 2021 Aug 12;64(15):10934-10950. doi: 10.1021/acs.jmedchem.1c00291. Epub 2021 Jul 26. J Med Chem. 2021. PMID: 34309393 Free PMC article.

2

Inhibitors of the immunoproteasome: current status and future directions.

Miller Z, Ao L, Kim KB, Lee W. Miller Z, et al. Curr Pharm Des. 2013;19(22):4140-51. doi: 10.2174/1381612811319220018. Curr Pharm Des. 2013. PMID: 23181576 Free PMC article. Review.

3

The immunoproteasome as a therapeutic target for hematological malignancies.

Miller Z, Lee W, Kim KB. Miller Z, et al. Curr Cancer Drug Targets. 2014;14(6):537-48. doi: 10.2174/1568009614666140723113139. Curr Cancer Drug Targets. 2014. PMID: 25059201 Review.

4

Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.

Miller Z, Kim KS, Lee DM, Kasam V, Baek SE, Lee KH, Zhang YY, Ao L, Carmony K, Lee NR, Zhou S, Zhao Q, Jang Y, Jeong HY, Zhan CG, Lee W, Kim DE, Kim KB. Miller Z, et al. J Med Chem. 2015 Feb 26;58(4):2036-41. doi: 10.1021/jm501344n. Epub 2015 Feb 17. J Med Chem. 2015. PMID: 25658656

5

A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease.

Yeo IJ, Lee MJ, Baek A, Miller Z, Bhattarai D, Baek YM, Jeong HJ, Kim YK, Kim DE, Hong JT, Kim KB. Yeo IJ, et al. Among authors: miller z. Sci Rep. 2019 Dec 5;9(1):18393. doi: 10.1038/s41598-019-54846-z. Sci Rep. 2019. PMID: 31804556 Free PMC article.

6

LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease.

Bhattarai D, Lee MJ, Baek A, Yeo IJ, Miller Z, Baek YM, Lee S, Kim DE, Hong JT, Kim KB. Bhattarai D, et al. Among authors: miller z. J Med Chem. 2020 Apr 9;63(7):3763-3783. doi: 10.1021/acs.jmedchem.0c00416. Epub 2020 Mar 30. J Med Chem. 2020. PMID: 32189500

7

Next-generation proteasome inhibitors for cancer therapy.

Park JE, Miller Z, Jun Y, Lee W, Kim KB. Park JE, et al. Among authors: miller z. Transl Res. 2018 Aug;198:1-16. doi: 10.1016/j.trsl.2018.03.002. Epub 2018 Mar 26. Transl Res. 2018. PMID: 29654740 Free PMC article. Review.

8

H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.

Lee MJ, Miller Z, Park JE, Bhattarai D, Lee W, Kim KB. Lee MJ, et al. Among authors: miller z. Sci Rep. 2019 Mar 11;9(1):4089. doi: 10.1038/s41598-019-40635-1. Sci Rep. 2019. PMID: 30858500 Free PMC article.

9

PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancer.

Park JE, Ao L, Miller Z, Kim K, Wu Y, Jang ER, Lee EY, Kim KB, Lee W. Park JE, et al. Among authors: miller z. PLoS One. 2013 Sep 9;8(9):e73732. doi: 10.1371/journal.pone.0073732. eCollection 2013. PLoS One. 2013. PMID: 24040045 Free PMC article.

10

A FRET-based approach for identification of proteasome catalytic subunit composition.

Park JE, Wu Y, Carmony KC, Miller Z, Sharma LK, Lee DM, Kim DY, Lee W, Kim KB. Park JE, et al. Among authors: miller z. Mol Biosyst. 2014 Feb;10(2):196-200. doi: 10.1039/c3mb70471h. Mol Biosyst. 2014. PMID: 24301521 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

285 results

Search Page